Log In
Print
BCIQ
Print
Print this Print this
 

vantictumab (anti-Frizzled) (OMP-18R5)

  Manage Alerts
Collapse Summary General Information
Company OncoMed Pharmaceuticals Inc.
DescriptionHuman HuCAL mAb targeting the Wnt pathway
Molecular Target Frizzled homolog 7 (FZD7)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$40.0M

$499.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today